Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice
BMC Pharmacology volume 11, Article number: A53 (2011)
Rosiglitazone is a thiazolidinedione derivative oral hypoglycemic agent active in both diabetic animal models and type 2 diabetic patients. Rosiglitazone is a high affinity ligand for the peroxisome proliferator-activated receptor gamma, which is responsible for the insulin-sensitizing action of the compound. Recent large clinical trials found an association between the antidiabetic drug rosiglitazone therapy and increased risk of cardiovascular adverse events.
The aim of this report is to elucidate the cardiac electrophysiological properties of rosiglitazone on control and diabetic murine ventricular papillary muscles using conventional microelectrode technique.
In control histidine-decarboxylase knock-out mice (HDC-KO) as well as in their wild-types (WT) rosiglitazone (1–30 μM) shortened AP duration at the 90% level of repolarization (APD90) and increased the AP amplitude (APA) in a concentration-dependent manner. Moreover, rosiglitazone reduced the maximum velocity of depolarization (Vmax). In diabetic animals we detected very similar effects.
The action potential changes caused by rosiglitazone probably can be explained by ion channel effects. The observed alterations may carry a serious proarrhythmic risk in case of overdose intoxication with rosiglitazone, especially in patients having multiple cardiovascular risk factors, like elderly diabetic patients.
About this article
Cite this article
Szebeni, A., Kovács, Á. & Kecskeméti, V. Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice. BMC Pharmacol 11 (Suppl 2), A53 (2011). https://doi.org/10.1186/1471-2210-11-S2-A53